Radiopharm Theranostics (RADX) Competitors $4.41 +0.10 (+2.32%) As of 07/22/2025 03:34 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsOwnershipSEC FilingsTrendsBuy This Stock RADX vs. ZURA, FATE, IOBT, GNLX, SEER, ONCY, MCRB, ACTU, OBIO, and SKYEShould you be buying Radiopharm Theranostics stock or one of its competitors? The main competitors of Radiopharm Theranostics include Zura Bio (ZURA), Fate Therapeutics (FATE), IO Biotech (IOBT), Genelux (GNLX), Seer (SEER), Oncolytics Biotech (ONCY), Seres Therapeutics (MCRB), Actuate Therapeutics (ACTU), Orchestra BioMed (OBIO), and Skye Bioscience (SKYE). These companies are all part of the "med - biomed/gene" industry. Radiopharm Theranostics vs. Its Competitors Zura Bio Fate Therapeutics IO Biotech Genelux Seer Oncolytics Biotech Seres Therapeutics Actuate Therapeutics Orchestra BioMed Skye Bioscience Zura Bio (NASDAQ:ZURA) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation. Which has higher valuation & earnings, ZURA or RADX? Radiopharm Theranostics has higher revenue and earnings than Zura Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZura BioN/AN/A-$45.39M-$0.70-2.40Radiopharm Theranostics$1.68M20.66N/AN/AN/A Is ZURA or RADX more profitable? Radiopharm Theranostics' return on equity of 0.00% beat Zura Bio's return on equity.Company Net Margins Return on Equity Return on Assets Zura BioN/A -42.84% -35.22% Radiopharm Theranostics N/A N/A N/A Do institutionals & insiders hold more shares of ZURA or RADX? 61.1% of Zura Bio shares are held by institutional investors. 22.1% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts prefer ZURA or RADX? Zura Bio currently has a consensus target price of $14.33, suggesting a potential upside of 753.17%. Radiopharm Theranostics has a consensus target price of $15.00, suggesting a potential upside of 240.14%. Given Zura Bio's higher possible upside, equities research analysts clearly believe Zura Bio is more favorable than Radiopharm Theranostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zura Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Radiopharm Theranostics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the media favor ZURA or RADX? In the previous week, Zura Bio had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for Zura Bio and 1 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 1.00 beat Zura Bio's score of 0.45 indicating that Radiopharm Theranostics is being referred to more favorably in the news media. Company Overall Sentiment Zura Bio Neutral Radiopharm Theranostics Positive SummaryZura Bio and Radiopharm Theranostics tied by winning 5 of the 10 factors compared between the two stocks. Get Radiopharm Theranostics News Delivered to You Automatically Sign up to receive the latest news and ratings for RADX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RADX vs. The Competition Export to ExcelMetricRadiopharm TheranosticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.98M$2.92B$5.48B$9.44BDividend YieldN/A2.49%4.01%4.02%P/E RatioN/A20.5328.3319.90Price / Sales20.66271.82411.9985.31Price / CashN/A41.6635.9658.29Price / BookN/A7.808.345.67Net IncomeN/A-$55.10M$3.24B$258.18M7 Day Performance-0.90%4.62%3.14%2.81%1 Month Performance0.46%17.99%10.99%13.53%1 Year PerformanceN/A2.21%34.25%17.68% Radiopharm Theranostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RADXRadiopharm TheranosticsN/A$4.41+2.3%$15.00+240.1%N/A$33.98M$1.68M0.00N/APositive NewsAnalyst ForecastZURAZura Bio3.2766 of 5 stars$1.96+51.9%$14.33+631.3%-52.9%$134.03MN/A-2.803High Trading VolumeFATEFate Therapeutics3.6854 of 5 stars$1.15+1.8%$3.83+233.3%-72.8%$131.79M$13.63M-0.77550IOBTIO Biotech3.6834 of 5 stars$2.00+5.8%$9.33+366.7%+26.6%$131.76MN/A-1.3430High Trading VolumeGNLXGenelux1.5369 of 5 stars$3.40+11.1%$17.75+422.1%+50.7%$128.39MN/A-3.8610SEERSeer2.1417 of 5 stars$2.12flat$3.00+41.5%+17.5%$124.80M$15.06M-1.50160ONCYOncolytics Biotech1.341 of 5 stars$1.32+5.6%$4.33+228.3%+21.6%$124.45MN/A-4.5530News CoverageUpcoming EarningsMCRBSeres Therapeutics3.4956 of 5 stars$14.08+0.8%$73.67+423.2%-49.6%$122.92M$126.32M-3.06330News CoverageACTUActuate Therapeutics1.748 of 5 stars$6.26+0.5%$20.50+227.5%N/A$122.82MN/A0.0010High Trading VolumeOBIOOrchestra BioMed2.9388 of 5 stars$3.17+0.6%$14.20+347.9%-59.9%$121.45M$2.89M-1.784SKYESkye Bioscience1.8148 of 5 stars$3.72+0.8%$16.60+346.2%-36.4%$115.23MN/A-4.5411 Related Companies and Tools Related Companies ZURA Competitors FATE Competitors IOBT Competitors GNLX Competitors SEER Competitors ONCY Competitors MCRB Competitors ACTU Competitors OBIO Competitors SKYE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RADX) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Radiopharm Theranostics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Radiopharm Theranostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
